Esomeprazole magnesium trihydrate , Pharmaceutical level , 217087-09-7

Synonym(s):
(S)-Omeprazole magnesium trihydrate

CAS NO.：217087-09-7

Empirical Formula: C34H38MgN6O7S2

Molecular Weight: 731.14

MDL number: MFCD07698573

EINECS: 669-839-3

PRODUCT Properties

• Melting point: 184-189°C (dec.)
• storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• solubility: Slightly soluble in water, soluble in methanol, practically insoluble in heptane.
• form: Solid
• color: White to off-white
• InChI: InChI=1S/2C17H18N3O3S.Mg.H2O/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;;/h2*5-8H,9H2,1-4H3;;1H2/q2*-1;+2
• InChIKey: VEVZQDGATGBLIC-UHFFFAOYSA-N
• SMILES: C(C1N=CC(C)=C(OC)C=1C)S1C2[N-]C3=CC(OC)=CC=C3N=2[Mg+2]2(O=S(CC3N=CC(C)=C(OC)C=3C)C3[N-]C4=CC(OC)=CC=C4N2=3)O=1.O
• CAS DataBase Reference: 217087-09-7(CAS DataBase Reference)

Description and Uses

esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.

1. Zollinger-Ellison syndrome
2. Peptic ulcer, site unspecified
3. Duodenal ulcer
4. Gastric ulcer
5. Gastro-oesophageal reflux disease

Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:

1. Gastro-Oesophageal Reflux Disease (GORD):
2. treatment of erosive reflux oesophagitis;
3. long-term management of patients with healed oesophagitis to prevent relapse;
4. symptomatic treatment of gastro-oesophageal reflux disease (GORD).

In combination with appropriate antibiotics for:

1. healing of duodenal ulcer associated with Helicobacter pylori;
2. eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
3. Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.
4. Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.
5. Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: Xn
• Risk Statements: 22
• WGK Germany: 3
• HS Code: 2933399090